unresectable urothelial carcinoma
CHMP gives positive opinion for Merck’s KEYTRUDA for unresectable or metastatic urothelial carcinoma
July 29, 2024Research and Development ADC, CHMP, Merck, Oncology, Urology, keytruda, metastatic urothelial carcinoma, unresectable urothelial carcinoma
Merck (known as MSD outside of the US and Canada) has announced that its anti-PD-1 therapy, in combination with Padcev …
Latest content
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
AI: an early warning system for patient safety
November 3, 2026
